OMERS ADMINISTRATION Corp Purchases 3,190 Shares of Zoetis Inc. (NYSE:ZTS)

OMERS ADMINISTRATION Corp raised its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 20.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,178 shares of the company's stock after purchasing an additional 3,190 shares during the period. OMERS ADMINISTRATION Corp's holdings in Zoetis were worth $3,125,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Zoetis by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after acquiring an additional 120,158 shares during the period. Geode Capital Management LLC grew its position in shares of Zoetis by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company's stock valued at $1,726,075,000 after purchasing an additional 190,137 shares during the last quarter. Polen Capital Management LLC increased its stake in shares of Zoetis by 17.5% during the fourth quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company's stock worth $1,219,237,000 after purchasing an additional 1,116,541 shares during the period. Wellington Management Group LLP lifted its holdings in Zoetis by 78.5% during the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock worth $1,133,755,000 after purchasing an additional 3,059,255 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in Zoetis by 13.3% during the 4th quarter. Northern Trust Corp now owns 6,426,394 shares of the company's stock worth $1,047,052,000 after purchasing an additional 755,893 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ZTS has been the topic of several recent research reports. Piper Sandler increased their price objective on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. Stifel Nicolaus lowered their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Morgan Stanley decreased their target price on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Finally, UBS Group dropped their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $212.75.

Zoetis Price Performance

ZTS stock traded up $2.68 during mid-day trading on Friday, hitting $163.03. The stock had a trading volume of 2,391,686 shares, compared to its average volume of 2,516,010. The firm has a fifty day simple moving average of $156.46 and a 200 day simple moving average of $165.31. The firm has a market capitalization of $72.58 billion, a P/E ratio of 29.80, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. During the same period last year, the firm posted $1.38 earnings per share. The firm's quarterly revenue was up 1.4% compared to the same quarter last year. As a group, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Insider Activity

In related news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares of the company's stock, valued at $2,682,770. This trade represents a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.